Carlo Artieri

Carlo Artieri has extensive experience in computational biology and bioinformatics. Carlo is currently serving as the Senior Director of Computational Biology Assay Research & Development at Freenome, where they lead a team of computational biologists, bioinformaticians, statisticians, and data scientists. Carlo is responsible for the design and analysis of development and validation studies for launching IVD products and collaborates closely with molecular research scientists and machine learning teams.

Prior to Freenome, Carlo was the Director of Computational Biology at Mission Bio, where they led the development of single-cell computational analysis, algorithms, and tools. Carlo played a key role in launching new computational methods for single-cell multiomics analysis.

Carlo also has a strong background in technology and bioinformatics. Carlo worked at Guardant Health, first as an Associate Director of Technology, where they led a team focused on developing improved cancer diagnostic assays incorporating novel omics approaches. Carlo then served as a Manager and Senior Manager of Bioinformatics, leading the computational analysis and development of MRD diagnostic assays for colorectal and lung cancers. Carlo also contributed to the design and development of Guardant OMNI™ assay and the deployment of Guardant's technology at MD Anderson Cancer Center.

Before their time at Guardant Health, Carlo worked as a Computational Research Scientist at Counsyl, where they focused on the development of circulating cell-free DNA sequencing technologies and implementing computational approaches for genomic variant detection.

Carlo's early career includes a postdoctoral fellowship at Stanford University, where they pioneered the use of ribosome footprinting for measuring allele-specific gene expression and protein translation. Carlo also worked as a Visiting Fellow at the National Institutes of Health, where they developed and implemented a comparative genomic approach for identifying and validating novel expressed transcripts and splicing variants.

Overall, Carlo Artieri has a strong track record in leading and driving advancements in computational biology, bioinformatics, and the development of innovative diagnostic assays for cancer research.

Carlo Artieri earned a Bachelor of Science degree in Biochemistry from Dalhousie University in 2003. Carlo then pursued a Master's degree in Biochemistry and Molecular Biology at Simon Fraser University from 2003 to 2005. Following that, they attended McMaster University where they completed their Doctor of Philosophy (Ph.D.) in Biology from 2005 to 2009.